Citation Impact
Citing Papers
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
2014
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
2012
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Luminal-B breast cancer and novel therapeutic targets
2011
Targeted therapies for breast cancer
2011
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
2012
Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
2012
Smarter drugs emerging in pancreatic cancer therapy
2014
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
2010
Combinatorial drug therapy for cancer in the post-genomic era
2012
mTOR Signaling in Growth Control and Disease
2012 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
2012
Liposomal drug formulations in cancer therapy: 15 years along the road
2011
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies
2011
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
2011
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Global cancer statistics
2011 Standout
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
2011
Progress of drug-loaded polymeric micelles into clinical studies
2014
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Prospects for MEK inhibitors for treating cancer
2014
Global Patterns of Cancer Incidence and Mortality Rates and Trends
2010 Standout
Ki67 expression in breast cancer
2016 Standout
Liposomes as nanomedical devices
2015 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
2012
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
2013 Standout
The PI3K Pathway in Human Disease
2017 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
2018 StandoutNobel
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Emerging targeted agents in metastatic breast cancer
2013
LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling
2013 StandoutNature
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Improving Prospects for Targeting RAS
2015
Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia
2008
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
2015
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
ALK1 as an emerging target for antiangiogenic therapy of cancer
2011
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
2011
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
2010
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program
2014
Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
2011
Antibody-Drug Conjugates in Cancer Therapy
2012
Natural product and natural product derived drugs in clinical trials
2014 Standout
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
2011
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Global cancer statistics, 2012
2015 Standout
Linkers Having a Crucial Role in Antibody–Drug Conjugates
2016
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
Breast cancer statistics, 2013
2013 Standout
Works of J. C. Bendell being referenced
A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
2011
A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).
2009
Phase II study of NK012 in relapsed small cell lung cancer.
2011
A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.
2010
A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.
2010
Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.
2011
Phase I and pharmacokinetic (PK) study of IHL-305 (pegylated liposomal irinotecan) in patients with advanced solid tumors
2009
A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results.
2011
Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma.
2010
Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
2011
Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
2007
Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).
2010
A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.
2010
A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.
2010
A phase I dose-escalation study of IMGN388 in patients with solid tumors.
2010